{
  "@context": "aku-v2",
  "@type": "clinical-syndrome",
  "@id": "vasc:vm:kasabach-merritt",
  "metadata": {
    "version": "2.0.0",
    "created": "2026-01-07T03:20:00.000Z",
    "updated": "2026-01-07T03:20:00.000Z",
    "contributors": ["knowledge-graph-agent"],
    "confidence": 0.92,
    "status": "pending-quality-check"
  },
  "classification": {
    "domain_path": "health-sciences/medicine/surgery/vascular/pathology/vascular-malformations",
    "type": "clinical-syndrome",
    "difficulty": "advanced",
    "importance": "high"
  },
  "content": {
    "title": "Kasabach-Merritt Phenomenon",
    "description": "Consumptive coagulopathy associated with kaposiform hemangioendothelioma or tufted angioma",
    "key_concepts": [
      {
        "concept": "Clarification",
        "details": "NOT associated with infantile hemangioma; occurs with KHE or tufted angioma only"
      },
      {
        "concept": "Pathophysiology",
        "details": "Platelet trapping within tumor causes profound thrombocytopenia and consumption of clotting factors"
      },
      {
        "concept": "Laboratory",
        "details": "Severe thrombocytopenia (<10,000), low fibrinogen, elevated D-dimer"
      },
      {
        "concept": "Treatment",
        "details": "Sirolimus (mTOR inhibitor) emerging as first-line; vincristine, corticosteroids historically used"
      }
    ],
    "clinical_significance": "Medical emergency with mortality up to 30% if untreated"
  },
  "provenance": {
    "primary_sources": ["Drolet BA et al. Pediatrics 2013"]
  }
}
